iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

KKR Contemplates Stake Sale in India's JB Pharma, Valued at $3 Billion

29 Feb 2024 , 11:40 AM

KKR & Co. is considering selling its majority stake in India's JB Chemicals & Pharmaceuticals Ltd. due to interest from possible purchasers, according to individuals familiar with the situation.

The US private equity group is trying to employ financial consultants to assist analyse the sale of its 53.8% share in the Mumbai-based company, according to the sources, who asked not to be identified because the topic is confidential. Other buyout companies and industry leaders have expressed preliminary interest in acquiring KKR's share, according to the individuals.

JB Pharma's shares have risen 68% in the last year, putting the business at little more than $3 billion.

 Considerations are still in the early stages, and no final decisions have been taken, according to the individuals, who added that KKR may opt not to pursue a transaction.

In 2020, KKR acquired a controlling share in JB Pharma from the founding Mody family, and it made an open bid for an additional 26% ownership. 

JB Pharma, founded in 1976, manufactures medications in fields such as gastrointestinal, hypertension, dermatitis, and diabetes, according to its website. It ships its pills, capsules, lotions, and other formulations to over 40 nations, including the United States.

KKR & Co. Inc., commonly known as Kohlberg Kravis Roberts & Co., is an American worldwide investment firm that manages a wide range of alternative asset classes, including private equity, energy, infrastructure, real estate, credit, and hedge funds through strategic partnerships.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • JB Pharma
  • JB Pharma News
  • JB Pharma Stake
  • JB Pharma Updates
  • KKR
  • KKR News
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
15 Apr 2024   |   12:16 PM
Images
15 Apr 2024   |   10:33 AM
Images
15 Apr 2024   |   09:44 AM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp